Affordable Access

deepdyve-link
Publisher Website

What do we know about the antibody responses to SARS-CoV-2?

Authors
  • Lagunas-Rangel, Francisco Alejandro1
  • Chávez-Valencia, Venice2
  • 1 Department of Genetics and Molecular Biology, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV), Mexico City, Mexico
  • 2 Department of Nephrology, Hospital General Regional Hospital No. 1, Instituto Mexicano del Seguro Social, Morelia, Michoacán, Mexico
Type
Published Article
Journal
Immunobiology
Publisher
Elsevier GmbH.
Publication Date
Jan 23, 2021
Volume
226
Issue
2
Pages
152054–152054
Identifiers
DOI: 10.1016/j.imbio.2021.152054
PMID: 33524881
PMCID: PMC7826124
Source
PubMed Central
Keywords
Disciplines
  • Review
License
Unknown

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide causing a pandemic with millions of infected people and deaths. Currently, the scientific community is working hard to develop a specific vaccine or treatment. However, since antibody production is an important part of the adaptive immune response, to develop vaccines and therapies, we must understand the antibody response to SARS-CoV-2 infection. In this work, we summarize the most important findings of antibody-mediated immunity against SARS-CoV-2 and highlight its role in the efficient use of plasma from convalescent patients and the direct application of antibodies as treatment.

Report this publication

Statistics

Seen <100 times